LBA50 Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK plus lung cancer: updated results from PROFILE 1014.
Mok, T Kim, D Wu, YL Nakagawa, K Mekhail, T Felip, E Cappuzzo, F Paolini, J Usari, T Wilner, K
Mok, T
Kim, D
Wu, YL
Nakagawa, K
Mekhail, T
Felip, E
Cappuzzo, F
Paolini, J
Usari, T
Wilner, K
Citations
Altmetric:
Abstract
Description
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
LBA50 Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK plus lung cancer: updated results from PROFILE 1014. 2017, 28(suppl_5): Ann Oncol